Modified IPCW model: A method for adjusting for bias in the estimation of overall survival due to the use of second and third line therapies in locally advanced or metastatic pancreatic cancer patients.

dc.contributor.authorEscobar, N. E. Iznaga
dc.contributor.authorLuaces, Patricia Lorenzo
dc.contributor.authorValdes, Lizet Sanchez
dc.contributor.authorSilva, Carmen Valenzuela
dc.contributor.authorRamos, Tania Crombet
dc.contributor.authorStrumberg, Dirk
dc.contributor.authorSchultheis, Beate
dc.contributor.authorEbert, Matthias Philip
dc.contributor.authorKerkhoff, Andrea
dc.contributor.authorHofheinz, Ralf
dc.contributor.authorBehringer, Dirk M.
dc.contributor.authorSchmidt, Wolfgang E.
dc.contributor.authorGoker, Erdem
dc.contributor.authorDe Doss, Sara
dc.contributor.authorKneba, Michael
dc.contributor.authorYalcin, Suayib
dc.contributor.authorOverkamp, Friedrich
dc.contributor.authorSchlegel, Frank
dc.contributor.authorMarkus
dc.date.accessioned2019-10-27T11:08:02Z
dc.date.available2019-10-27T11:08:02Z
dc.date.issued2017
dc.departmentEge Üniversitesien_US
dc.description53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET -- JUN 02-07, 2017 -- Chicago, ILen_US
dc.description.sponsorshipAmer Soc Clin Oncolen_US
dc.identifier.doi10.1200/JCO.2017.35.15_suppl.e15787
dc.identifier.issn0732-183X
dc.identifier.issn1527-7755
dc.identifier.urihttps://doi.org/10.1200/JCO.2017.35.15_suppl.e15787
dc.identifier.urihttps://hdl.handle.net/11454/32114
dc.identifier.volume35en_US
dc.identifier.wosWOS:000411931701173en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherAmer Soc Clinical Oncologyen_US
dc.relation.ispartofJournal of Clinical Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleModified IPCW model: A method for adjusting for bias in the estimation of overall survival due to the use of second and third line therapies in locally advanced or metastatic pancreatic cancer patients.en_US
dc.typeConference Objecten_US

Dosyalar